Novo Nordisk price target raised to DKK 300 from DKK 280 at HSBC
HSBC raised the firm's price target on Novo Nordisk to DKK 300 from DKK 280 and keeps a Hold rating on the shares. In a sector note on Healthcare, HSBC adjusted target prices on the prospects of the sector's relative outperformance potential for the second half of the year, noting that the Therapeutics space offering "